Resolution names Paul Sekhri chair
Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet
Resolution Therapeutics Ltd. announced the appointment of serial entrepreneur Paul Sekhri as chair alongside a £63.5 million ($83.5 million) series B round led by Syncona Ltd. Sekhri is president and CEO of vTv Therapeutics Inc. (NASDAQ:VTVT) and succeeds Lisa Bright. Resolution said it would use the proceeds from the B round to take its lead candidate macrophage cell therapy into the clinic to treat end-stage liver disease.
Illumina Inc. (NASDAQ:ILMN) is searching for a new general counsel following the departure of Charles Dadswell, who stepped down on Oct. 3. Illumina named Scott Davies acting general counsel and said Dadswell will remain an employee and adviser to the company's CEO and board until March 31, 2025. Davies joined Illumina in 2009 and was most recently VP, legal — chief corporate counsel...